Invasive mammary carcinoma is breast cancer that has grown beyond the layer of cells where it started and into surrounding breast tissue, gaining the ability to spread to lymph nodes or distant organs. It is the most common form of breast cancer and accounts for the vast majority of breast cancer diagnoses. The term covers several distinct subtypes that differ in how they look under a microscope, which genes drive them, how they respond to treatment, and how aggressively they behave. Understanding which subtype a person has matters enormously, because two invasive breast cancers can be as different from each other as two entirely separate diseases.
Ductal Versus Lobular and Why It Matters
The two most recognized histological types are invasive ductal carcinoma and invasive lobular carcinoma. Invasive ductal carcinoma is by far the more common, making up roughly 70 to 80 percent of all invasive breast cancers. Invasive lobular carcinoma accounts for about 10 to 15 percent. The rest are rarer forms like mucinous, tubular, and medullary carcinomas, each with its own characteristics.
These two major types are not just distinguished by where in the breast they originate. Lobular cancers almost always lack a protein called E-cadherin, which normally acts as a kind of glue holding cells together. Without it, lobular cancer cells tend to grow in single-file lines through the tissue rather than forming the dense lumps typical of ductal cancers. This growth pattern makes lobular carcinomas harder to detect on mammograms, because they often don’t form a well-defined mass. Gene expression comparisons between the two types show substantial molecular differences: one analysis identified over 1,400 genes with different activity levels between luminal A lobular and luminal A ductal cancers, and lobular tumors showed higher levels of immune-related gene signatures and higher expression of immune checkpoint targets like PD-L1 and PD-1.1Nature. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism
Molecular Subtypes
Beyond the microscope, gene expression profiling has reshaped how oncologists think about invasive breast cancer. Four molecular subtypes are now widely recognized: luminal A, luminal B, HER2-enriched, and basal-like.2Journal of Breast Imaging. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists These subtypes differ in how fast they grow, how likely they are to respond to specific drugs, and how they tend to behave over time.
Luminal A tumors are hormone receptor-positive and tend to be the slowest growing, with the best prognosis overall. Luminal B tumors are also hormone receptor-positive but grow faster and sometimes overexpress HER2. HER2-enriched tumors are driven by the HER2 protein and historically carried a poor prognosis, though targeted therapies have dramatically improved outcomes. Basal-like tumors, which overlap heavily with what clinicians call triple-negative breast cancer (negative for estrogen receptor, progesterone receptor, and HER2), tend to be the most aggressive and have the fewest targeted treatment options, though that picture is changing with immunotherapy.
Knowing the molecular subtype often matters more than knowing the histological type. A small, hormone receptor-positive invasive ductal carcinoma caught early has a fundamentally different treatment plan and outlook than a large, triple-negative tumor, even though both fall under the same “invasive mammary carcinoma” umbrella. Traditional factors like tumor size, lymph node involvement, and histological grade remain important, but molecular classification has added a layer of precision that increasingly drives treatment decisions.3Modern Pathology. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
How Invasive Breast Cancer Spreads
For a breast cancer to become invasive, tumor cells must break through the basement membrane, a thin structural barrier that separates the milk ducts or lobules from the surrounding tissue. Once through, they face a dense network of structural proteins called the extracellular matrix. Cancer cells degrade this matrix using enzymes, particularly a family called matrix metalloproteinases, which essentially chew through the scaffolding to open paths for tumor spread.4PubMed Central. Role of extracellular matrix in breast cancer development: a brief update
A related process involves tumor cells borrowing a program from normal embryonic development called epithelial-mesenchymal transition, or EMT. During EMT, cells shift from a stationary, tightly connected state to a more mobile, loosely attached state. Breast cancer cells that undergo this shift ramp up certain proteins that promote movement while turning down the adhesion molecules that would normally keep them in place.5PubMed Central. Epithelial-mesenchymal transition in breast cancer progression and metastasis This transition doesn’t just help cancer cells migrate; it has also been linked to drug resistance, making tumors harder to treat once they’ve spread.6PubMed. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions
Genetic Risk Factors
Most invasive breast cancers are not caused by a single inherited gene mutation. The majority arise from a combination of acquired mutations, hormonal exposures, aging, and lifestyle factors. But in a meaningful minority of cases, inherited mutations in specific genes substantially raise the risk.
BRCA1 and BRCA2 are the most well-known, but they are far from the only relevant genes. A large analysis of more than 113,000 women confirmed that protein-truncating variants in five genes — ATM, BRCA1, BRCA2, CHEK2, and PALB2 — were strongly associated with breast cancer risk. Mutations in BRCA1, BRCA2, PALB2, and several others carried higher risk specifically for estrogen receptor-negative disease, which tends to be more aggressive.7PubMed. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women
PALB2 deserves particular attention because it is less well-known than the BRCA genes but carries substantial risk. Women with PALB2 mutations face a risk of breast cancer roughly eight to nine times higher than the general population before age 40, and the cumulative risk reaches about 35 percent by age 70.8PubMed Central. Breast-Cancer Risk in Families with Mutations in PALB2 Though PALB2 mutations are rare, they appear in a meaningful proportion of families with strong histories of breast cancer.9PubMed. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer Genetic testing has expanded accordingly, now covering panels of genes well beyond BRCA1 and BRCA2.
Obesity, Inflammation, and Risk
Among modifiable risk factors, obesity stands out for its connection to invasive breast cancer, especially in postmenopausal women with hormone receptor-positive tumors. The link runs through chronic, low-grade inflammation. Fat tissue in obese individuals produces elevated levels of inflammatory molecules that boost aromatase activity, the enzyme responsible for making estrogen after menopause. More aromatase means more estrogen, which fuels the growth of hormone-sensitive tumors. Immune cells called macrophages accumulate in breast fat tissue and amplify this inflammatory cycle, and their presence has been tied not just to increased cancer risk but also to worse outcomes after diagnosis.10PubMed. Role of inflammation in obesity-related breast cancer
Imaging and Detection
Standard mammography remains the backbone of breast cancer screening for most women. Digital breast tomosynthesis, sometimes called 3D mammography, has improved detection over traditional 2D mammograms. But for women with dense breast tissue, which can hide tumors on mammograms, the picture gets more complicated.
In a head-to-head comparison in women with dense breasts, abbreviated breast MRI detected all 17 invasive cancers in the study group, while tomosynthesis caught only 7, a difference in invasive cancer detection rate of about 7 per 1,000 women screened.11PubMed Central. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women with Dense Breasts Undergoing Screening That sounds dramatic, and it is in terms of sensitivity. But when researchers modeled the population-level impact of adding supplemental MRI for women with extremely dense breasts, the extra benefit in deaths prevented was modest: roughly 0.1 to 0.2 additional deaths averted per 1,000 women screened over a lifetime, compared to tomosynthesis alone. Extending MRI to all women with heterogeneously or extremely dense breasts pushed that number up somewhat, to about 0.6 to 0.9 additional deaths averted per 1,000.12JAMA Internal Medicine. Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density The implication is that MRI catches more cancers, but not all of those additional catches translate into saved lives, partly because some detected cancers would never have become lethal. For individual women with very dense breasts and additional risk factors, supplemental MRI screening can make sense; for the broader population, the benefit-harm tradeoff is more nuanced.
Genomic Tests and the Chemotherapy Decision
One of the most consequential shifts in treating hormone receptor-positive, HER2-negative invasive breast cancer has been the use of genomic assays to decide whether chemotherapy is actually needed. The Oncotype DX test assigns a recurrence score based on the activity of 21 genes in the tumor. A landmark trial showed that for women with hormone receptor-positive, HER2-negative, node-negative breast cancer and mid-range recurrence scores, endocrine therapy alone produced outcomes virtually identical to those from adding chemotherapy: roughly 84 percent were free of invasive disease at nine years in both groups, and overall survival was essentially the same at about 94 percent.13PubMed Central. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer The exception was women aged 50 or younger with mid-range scores, who showed some benefit from adding chemotherapy.
This has spared a large number of women from chemotherapy’s side effects without compromising their outcomes. Even for very small tumors, the test can be informative: among small T1a and T1b tumors, a meaningful minority still had scores suggesting chemotherapy benefit.14PubMed. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer Tumor size alone, in other words, is not a reliable proxy for how aggressively a cancer needs to be treated.
Surgery and Lymph Node Management
Surgical treatment of invasive breast cancer has become steadily less radical over time. Sentinel lymph node biopsy has replaced routine full axillary lymph node dissection for most women with early-stage disease.15PubMed Central. Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer The idea is straightforward: identify and test the first one or two lymph nodes that drain the tumor area. If those come back clean, the rest almost certainly are too, and the patient can avoid the pain, reduced arm mobility, and lymphedema risk that come with removing many nodes.
A randomized trial confirmed this approach: among women with small breast cancers whose sentinel nodes were cancer-free, skipping the full dissection produced less pain and better arm function, and no cases of overt axillary recurrence appeared during follow-up.16PubMed. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer This shift represents one of the clearest examples in oncology of learning to do less when less is just as safe.
Drug Therapies by Subtype
Treatment of invasive breast cancer is increasingly tailored to the molecular subtype, and the drug landscape has expanded considerably.
Hormone Receptor-Positive Disease
For tumors driven by estrogen, endocrine therapy — drugs that either block the estrogen receptor or suppress estrogen production — remains foundational. CDK4/6 inhibitors, a class of drugs that halt cell division by blocking specific enzymes the cancer cell needs to multiply, have become standard additions for advanced hormone receptor-positive, HER2-negative breast cancer.17PubMed Central. CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment These drugs have meaningfully extended progression-free survival, though resistance eventually develops in many patients.18PubMed. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Endocrine resistance itself is a major challenge. In up to about 20 percent of patients with metastatic estrogen receptor-positive breast cancer who have been treated with aromatase inhibitors, mutations develop in the gene for the estrogen receptor (ESR1) that allow the receptor to stay active even without estrogen.19PubMed Central. ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer These mutations cluster in a specific region of the receptor and can drive tumor growth even while the patient is on endocrine therapy, making them a critical area of research and emerging clinical testing.20PubMed Central. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
HER2-Positive Disease
HER2-positive invasive breast cancers have benefited enormously from targeted therapies. The newest generation includes antibody-drug conjugates, which are essentially guided missiles: an antibody that homes in on HER2 on the cancer cell surface, linked to a powerful chemotherapy payload that is released once inside the cell. Trastuzumab deruxtecan, the most prominent of these, produced a response rate of about 61 percent and a median progression-free survival of over 16 months in patients with heavily pretreated HER2-positive metastatic disease.21PubMed. Trastuzumab deruxtecan for HER2+ advanced breast cancer The drug carries a potent chemotherapy component, a topoisomerase I inhibitor, connected to the antibody through a cleavable linker.22PubMed Central. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer What makes this class of drugs particularly interesting is the “bystander effect”: the chemotherapy payload can leak from the targeted cell and kill neighboring cancer cells that might not express HER2 themselves. This has expanded interest in using these drugs even in tumors with lower levels of HER2 expression.23PubMed. Trastuzumab deruxtecan in breast cancer
Triple-Negative Disease
Triple-negative breast cancer has historically had the fewest targeted options, but immunotherapy has begun to change that. Adding the checkpoint inhibitor pembrolizumab to chemotherapy before surgery boosted the rate of complete pathological response — meaning no remaining invasive cancer found in the surgical specimen — to about 65 percent, compared to roughly 51 percent with chemotherapy alone.24PubMed. Pembrolizumab for Early Triple-Negative Breast Cancer In the metastatic setting, the benefit depended on how much the tumor expressed PD-L1: patients whose tumors had high PD-L1 expression saw median overall survival improve from about 16 months to 23 months with pembrolizumab added to chemotherapy, while the benefit was less clear in tumors with lower expression.25PubMed. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
The Immune Landscape Inside the Tumor
How heavily a tumor is infiltrated by immune cells, particularly lymphocytes, has emerged as both a prognostic marker and a predictor of treatment response. Tumors with high levels of tumor-infiltrating lymphocytes are significantly less likely to fail neoadjuvant chemotherapy. One analysis found that having lymphocyte infiltration above a threshold of 10 percent was independently associated with roughly a 70 percent lower odds of nonresponse to chemotherapy.26PubMed Central. Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer In HER2-positive breast cancer, high lymphocyte counts have been associated with favorable prognosis, potentially because the immune response amplifies the effect of anti-HER2 drugs.27PubMed Central. Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Researchers are also drilling into which types of immune cells matter most. Studies examining CD4+, CD8+, and FOXP3+ lymphocytes in breast tumors found that specific combinations of these markers were better at predicting chemotherapy response than any single one alone.28PubMed Central. Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes The practical goal is to eventually use immune profiling to decide who truly needs aggressive treatment and who might safely receive less.
Dormancy and Late Recurrence
One of the most unsettling aspects of invasive breast cancer, particularly the hormone receptor-positive subtypes, is the possibility of late recurrence. Cancer cells can lie dormant in bone marrow, the liver, or other distant sites for years or even decades before reactivating. This dormancy is influenced by signals from the surrounding tissue and by the immune system, which can keep small clusters of cancer cells in check for long periods. When those restraining signals break down, the cells can begin growing again and give rise to detectable metastases.29PubMed Central. Unraveling the Mystery of Breast Cancer Dormancy: Insights into Genetic, Receptor, and Cellular Interactions Driving Late Recurrence
Understanding what flips this dormancy switch is an active area of investigation. Research has focused on the interplay between immune surveillance, changes in the local environment around dormant cells, and genetic or epigenetic alterations within the cancer cells themselves.30iMetaMed. Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches This is one reason extended endocrine therapy for five to ten years is now recommended for many women with hormone receptor-positive disease: it suppresses the estrogen signaling that dormant cells may need to wake up.
Racial Disparities in Diagnosis and Outcomes
Not everyone faces the same risk from invasive breast cancer. In a large analysis of U.S. data, Black women were about twice as likely to be diagnosed with triple-negative breast cancer compared to white or Asian women (roughly 21 percent versus 10 percent of diagnoses). After adjusting for tumor characteristics and treatment, Black women with triple-negative disease had a significantly higher risk of death, with about 39 percent greater all-cause mortality than white women with the same subtype.31PubMed Central. Racial disparities in health insurance, triple-negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States These disparities reflect a tangled web of biological differences in tumor biology, unequal access to care and insurance, later-stage diagnoses, and systemic factors that research is still working to fully disentangle.
Long-Term Side Effects of Treatment
Surviving invasive breast cancer often means living with treatment-related effects that persist long after therapy ends. A systematic review identified a wide spectrum of long-term consequences:
- Chemotherapy: peripheral nerve damage causing numbness or tingling in the hands and feet, and cognitive changes sometimes called “chemo brain.”
- Radiation: tissue scarring (fibrosis), a small increased risk of secondary cancers in the treated area, and a higher risk of heart disease, particularly when the left breast is irradiated.
- Endocrine therapy: bone thinning, joint pain, and metabolic changes including weight gain and cholesterol shifts.
- HER2-targeted therapy: heart muscle weakening, usually reversible but requiring monitoring.
Persistent fatigue, menopausal symptoms, lymphedema, and psychological distress cut across treatment types.32PubMed Central. Long-Term Side Effects of Breast Cancer Treatments: A Systematic Review Awareness of these long-term effects is part of why the field has pushed so hard to de-escalate treatment when safely possible, as described with genomic testing and sentinel node biopsy.
Liquid Biopsies and Circulating Tumor DNA
One of the most promising tools on the horizon for managing invasive breast cancer is the liquid biopsy, a blood test that detects fragments of tumor DNA circulating in the bloodstream. In early-stage breast cancer, there is preliminary evidence that circulating tumor DNA can be used to monitor how well treatment is working and to identify patients at high risk of relapse after surgery.33PubMed Central. Circulating Tumor DNA in Early and Metastatic Breast Cancer—Current Role and What Is Coming Next
A prospective study tracking both circulating tumor DNA and circulating tumor cells in patients with early-stage breast cancer found that the combined approach detected minimal residual disease before clinical relapse in every patient who eventually recurred, with a median lead time of roughly 28 months before relapse became detectable by standard imaging. A composite score integrating these blood-based measures stratified five-year recurrence risk dramatically: about 2 percent for low-score patients versus over 40 percent for high-score patients.34npj Breast Cancer. Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer This is still early-stage research and not yet part of routine practice, but it points toward a future where blood tests could guide how aggressively survivors are monitored and whether additional treatment is warranted after surgery.
Artificial Intelligence in Breast Cancer Pathology
AI is beginning to make inroads into how invasive breast cancer is diagnosed and characterized. Deep learning algorithms have shown consistency with expert pathologists in identifying and scoring tumor-infiltrating lymphocytes, assessing features of the tumor’s surrounding environment, and even predicting the expression of key biomarkers like HER2 and estrogen receptor status from standard tissue stain slides alone, without the specialized staining typically required.35PubMed Central. Artificial Intelligence in digital pathology of breast cancer, new era of practice? Separate work on automating the classification of invasive ductal carcinoma in digital pathology images has demonstrated accuracy in the mid-80 percent range, comparable to purpose-built models, using transfer learning approaches.36PubMed Central. Artificial intelligence in automatic classification of invasive ductal carcinoma breast cancer in digital pathology images The practical appeal is speed and consistency: AI could eventually serve as a second reader, flagging difficult cases and reducing diagnostic variability between pathologists, particularly in settings with limited specialist access.